While chances of her leaked plan to force lower drug prices in the United States getting through the Republican-controlled Senate are extremely small, House Speaker Nancy Pelosi, D-California, put biosimilars, including insulins, into the national conversation this week.
While chances of her leaked plan to force lower drug prices in the United States getting through the Republican-controlled Senate are extremely small, House Speaker Nancy Pelosi, D-California, put biosimilars, including insulins, into the national conversation this week.
The leaked plan proposes that the secretary of HHS should have the power to “to directly negotiate prices on the top 250 drugs with the greatest total cost to Medicare and the entire US health system without competition from at least [2] generic, biosimilar or interchangeable biologics on the market.”
Each year, the most expensive 250 drugs would be subject to review. Not only that, but the price would be available to all payers—not just Medicare, the document says.
The top 5 drug products with the highest total spending in 2016 accounted for approximately 10% of total prescription drug spending among large employer plans, Medicare Part D, and Medicaid. Among large employers, Humira ($4.9 billion) and Enbrel ($2.4 billion), both of which have FDA-approved but unlaunched biosimilar options, were responsible for the greatest share of spending.
The issue of drug pricing promises to continue over the next year, since, while numerous proposals have been issued by Republicans and Democrats alike, none have gained any momentum, given staunch industry opposition and a divided Washington.
Borrowing a bit from President Donald Trump’s International Pricing Index (IPI) proposal plan, the Pelosi plan would set an upper limit for the price reached in any negotiation as no more than 1.2 times, or 120% of, the volume-weighted average of price of 6 countries (Australia, Canada, France, Germany, Japan, and the United Kingdom).
Writing in The Federalist, Christopher Jacobs called that part of the plan “the de facto imposition of price controls.”
The plan comes with stiff, retroactive penalties for pharmaceutical firms that refuse to comply:
In addition, all 8000 drugs in Medicare Part B and D would have a new inflation rebate to deter price hikes. If a pharmaceutical company has raised the price of a drug in Part B or D above the rate of inflation since 2016, they can either lower the price or be required to pay the entire price above inflation in a rebate back to the government.
A report released by CMS last year found that Medicare and its beneficiaries spend $8.1 billion more on drugs than they would if payments were scaled by international price ratios.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.